Vibration training not only improved physical symptoms associated with multiple sclerosis, but it also improved cognitive functions including memory capacity and executive function.
A 3D mini brain, created from human skin cells, will be used to study myelin.
Those with MS allocate neural resources less effectively when faced with increased cognitive task demands, and this likely results in the increased mental fatigue those with the neurodegenerative disorder experience.
The FDA has approved a new drug named Ozanimod for the treatment of multiple sclerosis. Ozanimod binds to receptors in lymphocytes' surfaces, preventing them from reaching the brain. As the number of active lymphocytes decreases, the attack on the immune system diminishes.
Multiple sclerosis patients who received N-acetylcysteine treatments had improvements in metabolism in brain areas associated with cognition and attention.
Researchers link the Human Herpes Virus 6A to the development of multiple sclerosis.
A study of over 200,000 people found no evidence that vaccinations increase the risk of developing multiple sclerosis, or the onset of an initial MS episode.
A novel PET neuroimaging tracer detects abnormal inflammation in the cerebral gray matter of patients with secondary progressive multiple sclerosis.
Extracting nanosized exosomes from bone marrow stem cells and injecting them into mice, researchers reverse symptoms of multiple sclerosis.
Injecting extracellular vesicles from healthy mice into mice that had an MS-like disease resulted in the development of a relapse-remitting disease and active CD8+ cells, similar to that seen in human patients with multiple sclerosis. Examining the EVs in mice and humans with MS, researchers identified they contained fibrinogen, a protein normally associated with blood clotting and wound healing. According to researchers, the EVs with fibrinogen appear to activate the CD8+ immune cells. The findings could help with the development of new treatments for RRMS.
A study in mouse models of multiple sclerosis demonstrates a compound called sobetirome promotes remyelination, and a derivative of the compound can penetrate the blood-brain barrier to enable a tenfold increase in infiltration to the CNS. Researchers are confident their research will translate from mice into humans, providing a new avenue of treatment for MS.
18% of new patients treated at two Los Angeles hospitals for multiple sclerosis were misdiagnosed with the autoimmune disease. The misdiagnosed patients were often treated unnecessarily with medications designed for MS. From their findings, researchers report the most common alternative diagnosis was migraine.
